'Whether the substantial hybrid immunity present in India can protect against severe consequences of the disease remains to be seen.'
'Antibodies remain in the blood for at least seven to nine months.'
'Someone may have diabetes, but at what level the disease qualifies as a comorbid condition is something a doctor will decide upon and certify accordingly.'
In a move to plug gaps in the Insolvency and Bankruptcy Code (IBC), the ministry of corporate affairs (MCA) has proposed robust norms against avoidance transactions, wrongful trading, and inordinate delays via changes to look-back period and fixed timelines for the tribunals to reject or approve plans, among other measures. The MCA has proposed that the IBC should provide the adjudicating authority with 30 days for approving or rejecting a resolution plan under Section 31. If a decision is not made on the resolution plan within that period, the adjudicating authority will record reasons in writing for the same, the ministry has proposed.
If the vaccine is recommended for use as a booster against Omicron, it may significantly boost the demand for Covishield in India.
'There is no emergency of a third wave that we are rushing for booster doses.'
'We have to ensure the European situation does not occur in India and we don't see a spread like theirs.'
As the Omicron variant of Sars-CoV-2 takes centrestage, vaccine makers in India are of the view that scaling up the existing vaccines to make them more effective is possible.
The share of total health expenditure as part of the gross domestic product (GDP) went down to 3.3 per cent in 2017-18 from 3.8 per cent in the previous two years, according to the national health account data released on Monday by the health ministry. The share of government expenditure as part of total expenditure as well as GDP has gone up from from 3.78 per cent to 5.12 per cent between 2013-14 and 2017-18, which could also explain a decline seen in out of pocket expenditure in 2017-18. Health ministry also emphasised the increase in the government health expenditure as part of the total GDP from 1.15 per cent in 2013-14 to 1.35 per cent in 2017-18.
After ramping up production to meet the steep demand spike during the Covid-19 pandemic, Indian medical device makers are now struggling with idle capacity. According to industry estimates, around a third of the installed capacity, especially for consumables, disposables, small-ticket electronic items, etc., is lying unutilised. Sample this: India used to produce just 6.24 million pieces of PPE kits per annum before the pandemic, but by June this was ramped up to 233.87 million pieces per annum.
'Antiviral treatment will have no change. Spike protein change may affect the immunity protection.'
With around 2 million Covid vaccine doses likely to get wasted in December, leading hospital chains have now started to give it gratis to citizens. Sohini Das and Ruchika Chitravanshi report.
A nasal vaccine, one expert said, is a "fantastic idea" for two reasons -- one, it can potentially create sterile immunity, and two, it is easy to administer and thus scalable.
The Union health ministry has directed states to identify all left-out people and ensure everyone gets their Covid jab through initiatives such as workplace vaccination, as part of the government's "Har Ghar Dastak" campaign. Health Minister Mansukh Mandaviya held a review meeting on vaccination progress with Manipur, Meghalaya, Nagaland and Puducherry on Monday. In a tweet, the minister said, "Spoke about augmenting Govt's #HarGharDastak vaccine campaign. Requested help from religious leaders, NGOs & political groups to speed-up vaccination coverage." Health secretary Rajesh Bhushan has asked state officials that workplace vaccination should be organised for targeting people due for their doses.
Experts, however, feel that given the intensity of the second wave and the high single dose coverage, India is in a good position to avoid any drastic wave in the near future.
Tamil Nadu plans parallel programme with unique user IDs
Will syringe shortage puncture India's Covid vaccine plans?
Lack of clarity on data-sharing persists, public health experts sceptic about the pilot that was run in six Union territories as benchmark for national roll-out
'Demand is wonderful. We have crossed 10 million on many days.' 'The Swedish trade commissioner recently said, "You guys are vaccinating the entire Sweden in one day".'
In September, Bharat Biotech aimed to supply 35 million doses, and take this up to 55 million by October. This is still less than what the Indian government expects from the company.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances